Cost-effectiveness Evaluation of the 2021 US Preventive Services Task Force Recommendation for Lung Cancer Screening

JAMA Oncology ◽  
2021 ◽  
Author(s):  
Iakovos Toumazis ◽  
Koen de Nijs ◽  
Pianpian Cao ◽  
Mehrad Bastani ◽  
Vidit Munshi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cost Effectiveness ◽  
Cancer Screening ◽  
Task Force ◽  
Preventive Services ◽  
Lung Cancer Screening ◽  
Effectiveness Evaluation

scholarly journals Cost-Effectiveness of Smoking Cessation Interventions in the Lung Cancer Screening Setting: A Simulation Study

2021 ◽  
Author(s):  
Christopher J Cadham ◽  
Pianpian Cao ◽  
Jinani Jayasekera ◽  
Kathryn L Taylor ◽  
David T Levy ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Smoking Cessation ◽  
Cost Effectiveness ◽  
Cancer Screening ◽  
Task Force ◽  
Lung Cancer Screening ◽  
Cancer Registries ◽  
Web Based ◽  
Screening Programs ◽  
Life Years

Abstract Background Guidelines recommend offering cessation interventions to smokers eligible for lung cancer screening, but there is little data comparing specific cessation approaches in this setting. We compared the benefits and costs of different smoking cessation interventions to help screening programs select specific cessation approaches. Methods We conducted a societal-perspective cost-effectiveness analysis using a Cancer Intervention and Surveillance Modeling Network model simulating individuals born in 1960 over their lifetimes. Model inputs were derived from Medicare, national cancer registries, published studies, and micro-costing of cessation interventions. We modeled annual lung cancer screening following 2014 US Preventive Services Task Force guidelines plus cessation interventions offered to current smokers at first screen, including pharmacotherapy only or pharmacotherapy with electronic and/or web-based, telephone, individual, or group counseling. Outcomes included lung cancer cases and deaths, life-years saved, quality-adjusted life-years (QALYs) saved, costs, and incremental cost-effectiveness ratios. Results Compared with screening alone, all cessation interventions decreased cases of and deaths from lung cancer. Compared incrementally, efficient cessation strategies included pharmacotherapy with either web-based cessation ($555 per QALY), telephone counseling ($7562 per QALY), or individual counseling ($35 531 per QALY). Cessation interventions continued to have costs per QALY well below accepted willingness to pay thresholds even with the lowest intervention effects and was more cost-effective in cohorts with higher smoking prevalence. Conclusion All smoking cessation interventions delivered with lung cancer screening are likely to provide benefits at reasonable costs. Because the differences between approaches were small, the choice of intervention should be guided by practical concerns such as staff training and availability.

The US Preventive Services Task Force Recommendation on Lung Cancer Screening

JAMA ◽  
2021 ◽  
Vol 326 (5) ◽  
pp. 440
Author(s):  
Bryan S. Squires ◽  
Ronald Levitin ◽  
Inga S. Grills
Keyword(s):  
Lung Cancer ◽  
Cancer Screening ◽  
Task Force ◽  
Preventive Services ◽  
Lung Cancer Screening ◽  
The Us

scholarly journals Evaluation of Revised US Preventive Services Task Force Lung Cancer Screening Guideline Among Women and Racial/Ethnic Minority Populations

2021 ◽  
Vol 4 (1) ◽  
pp. e2033769
Author(s):  
Thomas J. Reese ◽  
Chelsey R. Schlechter ◽  
Lindsey N. Potter ◽  
Kensaku Kawamoto ◽  
Guilherme Del Fiol ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Screening ◽  
Ethnic Minority ◽  
Task Force ◽  
Preventive Services ◽  
Lung Cancer Screening ◽  
Minority Populations ◽  
Screening Guideline ◽  
Ethnic Minority Populations ◽  
Racial Ethnic

Computed Tomographic Screening for Lung Cancer

2014 ◽  
Author(s):  
Doraid Jarrar ◽  
Grace Y. Song ◽  
Scott Swanson
Keyword(s):  
Lung Cancer ◽  
Cost Effectiveness ◽  
Cancer Screening ◽  
Task Force ◽  
Lung Cancer Screening ◽  
The United States ◽  
Diagnostic Tools ◽  
Computer Tomographic ◽  
Computed Tomographic ◽  
Screening Cost

Lung cancer is the leading cause of cancer deaths worldwide. Although lung cancer screening has been advocated, for a long time level 1 evidence has been absent, leaving physicians with the challenge of treating patients with mostly incurable disease. Even in 2014, the 5-year survival for lung cancer will only be around 16% despite sophisticated imaging and diagnostic tools. Physicians are thus taking a more proactive route, including early screening for lung cancer and efforts to curb tobacco use. This review discusses lung cancer screening in the context of the National Lung Screening Trial, risk of overdiagnosis, cost-effectiveness, U.S. Preventive Services Task Force recommendations, lung cancer screening in the community, improving the specificity of lung cancer screening, and treatment options for early-stage lung cancer. Tables review key principles of computed tomographic screening, cost-effectiveness of computer tomographic screening, predictors of malignancy in the Pan-Canadian screening study model, and follow-up and management of newly detected indeterminate nodules. Figures show common causes of cancer death in the United States, estimated new cancer cases and cancer deaths in men and women, a four-stage system used in clinical and surgical evaluation of lung cancer, secondary prevention lung cancer screening goals, and a low-dose computer tomographic scan. This review contains 5 figures, 4 tables, and 31 references.

Lung cancer screening in the first year following US Preventive Services Task Force (USPSTF) recommendation.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e17512-e17512
Author(s):  
Lalit Aneja ◽  
Amishi Desai ◽  
Karen Alisa Braithwaite ◽  
Corinne Liu ◽  
Jeffrey Gary Schneider
Keyword(s):  
Lung Cancer ◽  
Cancer Screening ◽  
Task Force ◽  
Preventive Services ◽  
Lung Cancer Screening ◽  
First Year
Sign in / Sign up

Export Citation Format

Share Document